139356-34-6

Basic information

• Product Name: (3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol
• Synonyms: (3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol;[3S-(1α,3α,5β)]-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol
• CAS NO: 139356-34-6
• Molecular Formula: C₁₉H₄₂O₄Si₂
• Molecular Weight: 390.70538
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 139356-34-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Solubility: CDCl3, CD3OD
• CAS DataBase Reference: (3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol(139356-34-6)
• EPA Substance Registry System: (3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol(139356-34-6)

Safety Data

• Hazardous Substances Data: 139356-34-6(Hazardous Substances Data)

Usage

Description

(3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol is a complex organic compound characterized by its unique molecular structure. It is composed of a cyclohexane ring with a hydroxyl group attached to the methanol molecule. The compound also features two (1,1-dimethylethyl)dimethylsilyl groups connected to the 3rd and 5th carbon atoms of the cyclohexane ring through an oxygen atom. This intricate structure endows the compound with specific properties that make it suitable for various applications.

Uses

Used in Pharmaceutical Industry:
(3S,5S)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-cyclohexaneMethanol is used as an intermediate in the synthesis of Vitamin D compounds. Its unique structure plays a crucial role in the formation of these essential nutrients, which are vital for maintaining healthy bones, immune function, and overall well-being.
In the preparation of Vitamin D compounds, this compound serves as a key building block, facilitating the development of pharmaceutical formulations that can be used to treat or prevent Vitamin D deficiencies and related health issues. The compound's ability to be incorporated into the structure of Vitamin D molecules makes it a valuable asset in the pharmaceutical industry, contributing to the development of effective and targeted treatments for various health conditions.

Upstream product

• 138-59-0 shikimic acid 
• 40983-58-2 methyl shikimate 
• 101906-39-2 Methyl (3R,4R,5R)-3,5-Bis<(tert-butyl)dimethylsilyloxy>-4-hydroxycyclohex-1-ene-1-carboxylate 
• 262594-22-9 methyl (3S,5R)-3,5-di[(tert-butyldimethylsilyl)oxy]-cyclohex-1-enecarboxylate 
• 6973-02-0 (3R)-3r,4c,5t-trihydroxy-cyclohexane-c-carboxylic acid methyl ester 
• 139356-32-4 methyl (1s_n,3R,4s_n,5R)-3,5-di[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-[(imidazol-1-ylthiocarbonyl)oxy]-cyclohexanecarboxylate 
• 135711-62-5 methyl quinicate 
• 191916-39-9 methyl (-)-quinate 
• 77-95-2 D-(-)-quinic acid 
• 139356-33-5 (3S,5S)-3,5-bis[(tert-butyl)dimethylsilyloxy]-1-hydroxycyclohexane-1-carboxylic acid methyl ester 

Downstream Products

• 1443929-45-0 C₂₅H₄₇NO₂Si₂ 

Relevant articles and documents

Economical Process for Preparation of the 19-nor A Ring of Paricalcitol from (-)-Shikimic Acid

An economical and efficient means of preparing the 19-nor A ring, a key precursor of the vitamin D receptor (VDR) activator Paricalcitol, is here described. This process begins with commercially available (-)-shikimic acid and was easily scaled up to kilo

AMINO QUINOLINE DERIVATIVES INHIBITORS OF HCV

A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are defined herein, and methods of treating HCV infection in a patient are disclosed.

HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES

Hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein The HDAC inhibitor moiety can be modelled after an HDAC inhibitor selected from the group consisting of tπchostatm A, sodium butyrate, valpro